SNK01 在中度阿尔茨海默病参与者中的 I/IIa 期研究
一项 I/IIa 期研究,旨在评估 SNK01 对中度阿尔茨海默病参与者的安全性、耐受性和探索性疗效
The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are:
- Is SNK01 safe and tolerable when administered every 3 weeks for up to 1 year as an intravenous infusion
- Can SNK01 administration improve cognitive assessment scores and biomarkers
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:Study Director
- 电话号码:949-396-6830
- 邮箱:trials@nkgenbiotech.com
学习地点
-
-
Ontario
-
Ottawa、Ontario、加拿大、K1Z 1G3
- 撤销
- Ottawa Memory Clinic
-
-
-
-
California
-
Glendale、California、美国、91206
- 招聘中
- Behavioral Research Specialists, LLC
-
接触:
- Harry Chung
- 电话号码:(888) 255-5798
- 邮箱:harry@brstrials.com
-
Santa Ana、California、美国、92705
- 招聘中
- Syrentis Clinical Research
-
接触:
- Nikole Bo
- 电话号码:714-542-3008
- 邮箱:nbo@syrentis.com
-
Tarzana、California、美国、91356
- 撤销
- Valiance Clinical Research
-
-
Florida
-
Maitland、Florida、美国、32751
- 招聘中
- K2 Medical Research
-
接触:
- Adaliz Rodriguez
- 电话号码:407-500-5252
- 邮箱:adaliz.rodriguez@k2med.com
-
Orlando、Florida、美国、32804
- 招聘中
- AdventHealth Research Institute
-
接触:
- Ana Chavarro Rendon
- 电话号码:407-609-9040
- 邮箱:cfd-sneuroscienceresearch@adventhealth.com
-
-
New Jersey
-
Newark、New Jersey、美国、07107
- 招聘中
- Rutgers Health
-
接触:
- Kelly Saverino
- 电话号码:973-972-1268
- 邮箱:kcs143@njms.rutgers.edu
-
-
New York
-
Albany、New York、美国、12208
- 招聘中
- Alzheimer's Disease Research Center
-
接触:
- Laura Wang
- 电话号码:518-426-0575
- 邮箱:lwang@naaresearch.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
The participant or their legally authorized representative must be willing and able to give their informed consent in writing and comply with the requirements of this study protocol. Informed consent for participants or their legally authorized representative and caregivers will be obtained before any trial-related activity. (Trial-related activities are any procedure that would not be performed during normal treatment of the participant).
-
Participants must have a reliable study partner/caregiver (per investigator judgement for instance a family member, partner etc., guardian (must be always the same person)) who is in close contact with the patient, available on call and who is able to contribute to the assessment of the ratings of the functional endpoints at specific study visits. This person will be able to communicate in the language in which the participant is being assessed and should also serve as a backup contact for the study site. The study partner/caregiver must sign a separate informed consent form which describes their contributions during the study.
-
Patients with diagnosis of Alzheimer's dementia according to the recommendations from the 2011 National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
-
Age 40 to 85 years old.
-
Patients must have at least 6 years of formal education and fluency in the test language as verbally confirmed by the patient or their legally authorized representative and documented by the study investigator.
-
Female participants of childbearing potential must have a negative urine pregnancy test at Screening and Visit 1 before first administration of the study drug. Females of childbearing potential are defined as those who are not surgically sterile or who are not post-menopausal (i.e.: no menses for at least 1 year). Male and female participants of reproductive potential must also agree to abstinence or use acceptable form(s) of effective contraception during the study and for 30 days after the final dose of the study drug. Acceptable methods of contraception include the following:
- Condoms, sponges, foams, gels, diaphragms, or intrauterine device (IUD).
- Hormonal birth control for 30 days prior to administration of the study drug.
- A vasectomized sexual partner.
-
Positive evidence for a diagnosis of AD via amyloid positron emission tomography (Amyloid PET) of the brain within the past six months.
-
CDR-SB score of ≥ 9.5 and <16.0.
Exclusion Criteria:
- Substantial concomitant cerebrovascular disease defined as Fazekas Grade 3.
- History of a stroke/intracranial hemorrhage temporally related to the onset of worsening of cognitive impairment in the opinion of the investigator.
- Any substance use disorder that has not been in remission for at least 12 months
- Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years.
- Uncontrolled cardiovascular illnesses such as chronic congestive heart failure (with or without oedema), tachycardia, arrhythmias, uncontrolled hypertension.
- History of cerebrovascular accident or transient ischemic attack (TIA), or unexplainable loss of consciousness within the last year.
- Significant pulmonary disease predisposing to hypoxia.
- Significant ischemic heart disease, myocardial infarction within the last two years and/or with residual angina, orthopnea, conduction defects (ECG), or any other clinically significant heart disease classified as NYHA III or IV.
- Significant liver disease (for example cirrhosis, active hepatitis B and C, primary or metastatic liver neoplasm).
- Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined during screening.
- Significant gastrointestinal disorders (for example gastrointestinal bleeding within the last two years, malabsorption syndromes, post-gastrectomy, or active peptic ulcer disease).
- Immunological disorder such as per investigator judgement clinically significant allergies, Lupus erythematodes, or scleroderma.
- Uncontrolled/Unstable hematological disease (regardless of cause) such as refractory anemia or refractory myelosuppression.
- Neurological disease (such as: Lewy body dementia - primary diagnosis, Huntington's disease, Parkinson's Disease, encephalitis, epilepsy, vascular or multi-infarct dementia, stroke, congenital mental deficiency, multiple sclerosis) and psychiatric disorders (such as schizophrenia, or intellectual disability), or any other disorders impacting cognitive function.
- Unstable/uncontrolled major depression or anxiety within the last 12 months.
- History of seizures in the past three years.
- Uncontrolled endocrine disease such as uncontrolled diabetes mellitus or manifest hyperthyroidism, in the opinion of the investigator.
- Severe renal impairment defined as a GFR < 30 mL/min/1.73 m2 in the screening lab report
- Infection with human immunodeficiency virus (HIV), hepatitis B, hepatitis C, or any other infection or active systemic disease.
- Currently being treated with anticoagulants (except aspirin at or below a prophylactic dose).
- Participants who are taking medications for AD, like memantine or acetylcholinesterase inhibitors (AChEI) that exceeds the normal recommended dose range or have not achieved a stable dose for the 30 days prior to enrollment.
- Any contraindication for performing a brain MRI and/or Amyloid PET scan.
- Any participant whose safety the investigator considers to be at risk from this trial's intervention.
- Participants with any medically unstable/uncontrolled conditions.
- Any suicidal behavior in the past 2 years (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior).
- Any suicidal ideation of type 4 or 5 in the C-SSRS in the past 3 months (i.e. active suicidal thought with intent but without specific plan, or active suicidal thought with plan and intent).
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:顺序分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:SNK01
SNK01 will be administered as an IV infusion Q3W for up to 1 year. |
SNK01 is a novel cell-based, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug |
|
安慰剂比较:Placebo
Placebo will be administered as an IV infusion Q3W for up to 1 year. |
Sodium Lactate Hartmann's Solution |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of participants with dose-limiting toxicity
大体时间:3 weeks
|
DLTs will be assessed by the review of labs, PE and AEs |
3 weeks
|
|
Maximum tolerated dose determination
大体时间:3 weeks
|
Determine the maximum tolerated dose based on the evaluation of the number of participants who experience a DLT which will then determine the RP2D. |
3 weeks
|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
大体时间:1 Year
|
Evaluate the safety and tolerability of SNK01 assessed by labs, PE and AEs |
1 Year
|
|
Preliminary efficacy in cognitive assessment scores of CDR-SB
大体时间:1 Year
|
Measure changes in cognitive assessment of CDR-SB from baseline |
1 Year
|
|
Preliminary efficacy in cognitive assessment scores of MMSE
大体时间:1 Year
|
Measure changes in cognitive assessment of MMSE from baseline |
1 Year
|
|
Preliminary efficacy in cognitive assessment scores of NPI
大体时间:1 Year
|
Measure changes in cognitive assessment of NPI from baseline |
1 Year
|
|
Preliminary efficacy in cognitive assessment scores of ADCS-ADL-Severe
大体时间:1 Year
|
Measure changes in cognitive assessment of ADCS-ADL-Severe from baseline |
1 Year
|
|
Preliminary efficacy in cognitive assessment scores of ADAS-Cog
大体时间:1 Year
|
Measure changes in cognitive assessment of ADAS-Cog from baseline |
1 Year
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Changes in CSF biomarkers (pTau 181, Aβ42/40, GFAP, NfL)
大体时间:1 Year
|
Measure changes in CSF biomarkers as changed from baseline |
1 Year
|
|
Changes in plasma biomarkers (pTau 181, Aβ42/40, GFAP, NfL)
大体时间:1 Year
|
Measure changes in Plasma biomarkers as changed from baseline |
1 Year
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- SNK01-AD01
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.